Cargando…

ZNF542P is a pseudogene associated with LDL response to simvastatin treatment

Statins are the most commonly prescribed cardiovascular disease drug, but their inter-individual efficacy varies considerably. Genetic factors uncovered to date have only explained a small proportion of variation in low-density lipoprotein cholesterol (LDLC) lowering. To identify novel markers and d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kyungpil, Theusch, Elizabeth, Kuang, Yu-Lin, Dose, Andrea, Mitchel, Katrina, Cubitt, Celia, Chen, Yii-Der I., Krauss, Ronald M., Medina, Marisa W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102286/ https://www.ncbi.nlm.nih.gov/pubmed/30127457 http://dx.doi.org/10.1038/s41598-018-30859-y

Ejemplares similares

Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation
por: Kim, Kyungpil, et al.
Publicado: (2014)

Genetic variants modulate gene expression statin response in human lymphoblastoid cell lines
por: Theusch, Elizabeth, et al.
Publicado: (2020)

Participant-derived cell line transcriptomic analyses and mouse studies reveal a role for ZNF335 in plasma cholesterol statin response
por: Theusch, Elizabeth, et al.
Publicado: (2023)

Correction: RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin
por: Medina, Marisa W., et al.
Publicado: (2013)

RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin
por: Medina, Marisa W., et al.
Publicado: (2012)

MiR-542-3p Suppresses Neuroblastoma Cell Proliferation and Invasion by Downregulation of KDM1A and ZNF346
por: Wei, Qiang, et al.
Publicado: (2020)

GeneFishing to reconstruct context specific portraits of biological processes
por: Liu, Ke, et al.
Publicado: (2019)

Complementary Therapy to Target LDL Cholesterol: The Role of the Ezetimibe/Simvastatin Combination
por: Neal, Ryan C, et al.
Publicado: (2006)

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
por: Farnier, Michel, et al.
Publicado: (2014)

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort
por: Kitzmiller, Joseph P., et al.
Publicado: (2014)

Séminaire Bourbaki : exposés 525-542
por: Dold, A, et al.
Publicado: (1980)

Pseudogenes
por: Tutar, Yusuf
Publicado: (2012)

Undifferentiated Induced Pluripotent Stem Cells as a Genetic Model for Nonalcoholic Fatty Liver Disease
por: Muñoz, Antonio, et al.
Publicado: (2022)

Soy milk versus simvastatin for preventing atherosclerosis and left ventricle remodeling in LDL receptor knockout mice
por: Santos, L., et al.
Publicado: (2017)

542 Identifying Psychosocial Factors Impacting Burn Survivors
por: Kilmer, Debra, et al.
Publicado: (2023)

Australia and New Zealand renal gene panel testing in routine clinical practice of 542 families
por: Tanudisastro, Hope A., et al.
Publicado: (2021)

SUN-542 The Effect of Energy Deprivation on Metabolic Hormone Responses to Meals
por: Shekhar, Skand, et al.
Publicado: (2020)

Pseudogene.org: a comprehensive database and comparison platform for pseudogene annotation
por: Karro, John E., et al.
Publicado: (2007)

LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor™) in Thai hypercholesterolemic subjects – a randomized crossover study, the first report from Thailand
por: Wiwanitkit, Viroj, et al.
Publicado: (2002)

Reaching target LDL cholesterol has become more affordable with launch of ezetimibe/simvastatin combination in South Africa
Publicado: (2010)

The GENCODE pseudogene resource
por: Pei, Baikang, et al.
Publicado: (2012)

Pseudogenes in Human Cancer
por: Poliseno, Laura, et al.
Publicado: (2015)

Role of Pseudogenes in Tumorigenesis
por: Hu, Xinling, et al.
Publicado: (2018)

Pseudogenes in Cardiovascular Disease
por: Qi, Yanyan, et al.
Publicado: (2021)

Preludes and fugues BWV 544, 541, 546, 542 and 536
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1992)

Role of miRNA‐542‐5p in the tumorigenesis of osteosarcoma
por: Zhu, Tengjiao, et al.
Publicado: (2020)

542 Mobile Burn Response Teams: A Scoping Review
por: Fuchko, Danielle H, et al.
Publicado: (2022)

Pharmacological Responses of the G542X-CFTR to CFTR Modulators
por: Fang, Xinxiu, et al.
Publicado: (2022)

The human ABC transporter pseudogene family: Evidence for transcription and gene-pseudogene interference
por: Piehler, Armin P, et al.
Publicado: (2008)

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004)

Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment
por: Kaddurah-Daouk, Rima, et al.
Publicado: (2011)

Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study
por: Kaddurah-Daouk, Rima, et al.
Publicado: (2010)

542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19
por: Brock, Patricia, et al.
Publicado: (2021)

Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men
por: Faghihnia, Nastaran, et al.
Publicado: (2012)

Recognizing the pseudogenes in bacterial genomes
por: Lerat, Emmanuelle, et al.
Publicado: (2005)

The PCNA pseudogenes in the human genome
por: Stoimenov, Ivaylo, et al.
Publicado: (2012)

Pseudofam: the pseudogene families database
por: Lam, Hugo Y. K., et al.
Publicado: (2009)

The Extinction Dynamics of Bacterial Pseudogenes
por: Kuo, Chih-Horng, et al.
Publicado: (2010)

CircRNA-derived pseudogenes
por: Dong, Rui, et al.
Publicado: (2016)

HMGA1-pseudogenes and cancer
por: De Martino, Marco, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9a58pbd1vsn8hivi0bvmh3m5se